Ann: Bronchiectasis Phase 3 Trial Milestone , page-4

I vaguely recall a broker call from a few years ago that mentioned bronchitol for bronchiectasis was the real money spinning - bronchitol for CF was only secondary.

If you see the trials history, it is obviously that in the early days they focused more on bronchiectasis but switched over to taking CF indication to the market in 07-08 timeframe.


Another significant point is that is there currently no medication prescribed specifically for bronchiectasis suffers so its basically a greenfield with market size of 600k vs CF 80k.


In summary... huge oppurunity if data is good!


Question: if p3 trial results are bad from the outset, is it possible for the co to cancel the trial in the early days in order to save money? If this is the case, I assume that if pxs mgt took bronchiectasis trial to completion then the result must be good.